

Management of Pharmacotoxicologic Side Effects using Novel SONAPS Technologies

Hosein Najafpour ¹, and Bahram Alamdary Badlou ^{2*}

¹ SONAPS Clinic. Research and Development Dept. Tehran, Iran

² BB Advies and Research, Research and development Dept. Zeist, The Netherlands.

Corresponding Author: Bahram Alamdary Badlou (CEO), BBAdvies and Research, Research and Development Dept. Zeist, The Netherlands.

Received date: February 28, 2022; **Accepted date:** March 10, 2022; **Published date:** April 10, 2022

Citation: Hosein Najafpour and Bahram Alamdary Badlou (2022) Management of Pharmacotoxicologic Side Effects using Novel SONAPS Technologies. *J. Pharmaceutics and Pharmacology Research*, 5(5); DOI:10.31579/2693-7247/054

Copyright: © 2022 Bahram Alamdary Badlou, This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Patients who are daily suffering from drug abuse and pharmacotoxicologic side effects causing unnecessary hospitals' visits, which unintentionally increase morbidity and mortality rate in- Hospital that the underlying mechanism still is not elucidate completely.

Recently different research study data showed how pharmacotoxicologic (un-)known drugs, biosimilars can cause (ir-)reversible hematologic, cardiovascular diseases [1-4], chronic tetralogy/pentology of Fallot with complex cyanotic-thrombocytopenic- Erythrocytosis side effects that 19 years Medicare & Medicaid no Medics could help for instance, the case that we reported [2].

Unfortunately, still there is not completely clarified how the different administered drugs and vaccines (COVID-19 vaccines especially) can cause (ir-) reversible and incontrollable small and/or major side effects, resulting in an increase in morbidity and mortality rates [3-8].

In the last year's research and developments opened new techniques to manufacture the biological blood-derived drugs prepared from either biological sources or waste products. Besides, these kinds of (un-)known biologic products are administrating directly as (un-)processed components- with limited both additives or anticoagulants, and/or in combination with admitted inconspicuously intravenous. Additionally, (semi-)biological drugs potentially considered as contaminated products, however. The biological types of antigens might increase morbidity and mortality rate, after drugs abuse, via induction of autoimmune diseases, post transfusion. Besides, raiding evidences show that the bio-similar and biological drugs have unknown (final) formulation, which might cause small metabolites, which could not being tracked by available tools, globally. Recall, the most important hypothesis is that administrating such biological drugs have no side effects.

Now we are observing pharmacotoxicologic side effects induced by bio-similar / biological drugs and vaccines, world widely (2-8), becomes a routine on one hand. On the other hand, the main formulation of non-biologic chemical drugs and vaccines supposed to be known and the standard formula with final concentration, and their so-called "final added elements and metabolites" (FAEM) should be (potentially possible) measurable, and changed by the different technologies and interventions. Furthermore, the FAEM's infections in either biologic and/or non-biologic drugs should be manageable, initially.

Other kinds of painkillers are (non) herbal prescriptions, which are mainly

made from herbal (un)known sources causing increased morbidity and in-hospital mortality rates, however [4-6]. There is no gold standard for the usage of herbal prescriptions, universally. Although, all side effects and allergic reactions are also not described and determined, appropriately.

Our novel researched and developed novel technologies so-called the Signature of Nervous Auricular Pulse System' (SONAPS) Diagnostic and Treatments (D&T) is helping better determine namely 1. Diagnosis of the underlying (ir-) responsiveness/ (ir-)reversibility/ (in-)dependency of certain amount (quantity) and bioavailability (quality) of administrated drugs for certain patients, based on their personalized bio-variability, which eventually resulting in 2. An appropriate (Treatments) and either a significant decreased in amount (quantitative) of drugs usage or an increasing effectiveness (qualitative) of administered drugs for determined period [1]. Beside, we have recently shown that it is possible to recover/heal/regenerate some patho- physiological process without using certain drugs i.e. a confirmed case with Diabetes Mellitus type 1, who was insulin-dependent (2-3 injections per day), after our developed SONAPS D&T become insulin-independent, periodically (paper submitted for publication).

Take home message is in 21th Century, we have to try to D&T certain patients, without using any drugs, as much as possible. From the time that human being is started using chemical drugs, the side effects, morbidity and mortality rates increased significantly. In a perfect world, if every treating Physician changes their D&T, as such that consider to prioritize either reducing drugs prescription, or minimal drugs amount, might all hazardous drugs abuse being decreased to zero, world widely.

References

1. Bahram Alamdary Badlou, and Hosein Najafpour. (2020) Management of Platelets in a Persian Girl with the Tetralogy Pentology of Fallot. 1(1): 1-10. doi:https://doi.org/10.37191/Mapsci-2582-7367-1(1)-002.
2. Bahram Alamdary Badlou. (2019) Admitting unknown biosimilar- drugs affects thrombosis and haemostasis processes. Editorial - Archives of Pharmacology and Therapeutics, 1:2: 57-58.
3. Fridell M, Bäckström M, Hesse M, Krantz P, Perrin S, Nyhlén A. (2019) Prediction of psychiatric comorbidity on premature death in a cohort of patients with substance use disorders: a 42-

- year follow-up. BMC psychiatry. 19(1):150.
4. EMCDDA. Mortality among drug users in Europe: New and old challenges for public health. 2015. European Monitoring Centre for Drugs and Drug Addiction. Portugal.
 5. Bartu A., Freeman NC., Gawthorne GS., Codde JP., Holman CD. (2004) Mortality in a cohort of opiate and amphetamine users in Perth, Western Australia. Addiction. 99(1):53- 60.
 6. Nyhlén A, Fridell M, Hesse M, Krantz P. (2011) Causes of premature mortality in Swedish drug abusers: a prospective longitudinal study 1970–2006. Journal of forensic and legal medicine. 18(2):66-72.
 7. Visentin GP, Liu CY. (2007) Drug-induced thrombocytopenia. Hematology/oncology clinics of North America. 21(4):685-696.
 8. Pishko, A.M., Bussel, J.B. & Cines, D.B. (2021) COVID-19 vaccination and immune thrombocytopenia. Nat Med 27, 1145–1146.



This work is licensed under Creative Commons Attribution 4.0 License

To Submit Your Article Click Here:

[Submit Manuscript](#)

DOI: [10.31579/2688-7517/054](https://doi.org/10.31579/2688-7517/054)

Ready to submit your research? Choose Auctores and benefit from:

- fast, convenient online submission
- rigorous peer review by experienced research in your field
- rapid publication on acceptance
- authors retain copyrights
- unique DOI for all articles
- immediate, unrestricted online access

At Auctores, research is always in progress.

Learn more <https://auctoresonline.org/journals/pharmaceutics-and-pharmacology-research>